2Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999, 341 (21) : 1565 - 1571.
3张之南，血液病诊断与疗效标准．2版．北京:科学出版社．1998．373—376．
4Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple mycloma after single - agent thalidomide : identification of prognostic factors in a phase 2 study of 169 patients. Blood, 2001, 98 (2): 492-494.
5Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives sugment natural killer cell cytotxicity in multiple myeloma. Blood, 2001, 98 (1): 2210-2216.
6Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96 (9) : 2943 -2950.
